Vivos Therapeutics reports 212% rise in Nevada patient referrals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
August 25, 2026 8:45 AM EDTLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Vivos or the Company) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (OSA) and other sleep disorders, today announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior six-week period. Since June 1, the total average weekly number of referrals has risen nearly five-fold and has continued to grow week... More
